Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) Surges by 88%
In a groundbreaking development, Adial Pharmaceuticals, Inc. (NASDAQ: 
ADIL) has unveiled promising findings in the treatment of Alcohol Use Disorder (AUD) with its lead investigational drug, AD04 (low-dose ondansetron). A recently published peer-reviewed article showcases the remarkable clinical results, robust safety profile, and exceptional patient compliance observed during the trials.
The study, featured in the European Journal of Internal Medicine, delves into the comprehensive analysis of AD04's liver safety profile compared to a placebo in individuals with AUD and a specific genetic profile. With AUD posing significant health risks and contributing to alcohol-associated liver disease (ALD), the need for effective treatments is paramount.
Remarkably, low-dose AD04 demonstrated minimal impact on liver injury markers, such as ALT, AST, and Serum Bilirubin, compared to placebo. Notably, the treatment did not adversely affect GGT levels, a key indicator of alcohol consumption, further underscoring its safety and tolerability. The study also highlighted AD04's outstanding safety profile, with a low occurrence of adverse events and high medication compliance, a rarity in alcohol treatment literature.
Cary Claiborne, CEO of Adial, hailed the publication as a significant milestone in addressing the critical needs of individuals suffering from AUD and ALD. He emphasized AD04's potential to revolutionize AUD treatment by offering a precision medication tailored to individuals with a specified genetic background.
With AD04 paving the way for precision treatments, tailored interventions for AUD patients could soon become a reality. This groundbreaking advancement not only promises to curb alcohol consumption but also holds the potential to mitigate liver damage in affected populations, offering hope to millions worldwide.
Technical Outlook
Adial Pharmaceuticals, Inc. (ADIL) stock is trading above the respective Moving Averages (MA) with a Relative Strength Index (RSI) of 65.30 indicating room for continuous growth.
ADIL) has unveiled promising findings in the treatment of Alcohol Use Disorder (AUD) with its lead investigational drug, AD04 (low-dose ondansetron). A recently published peer-reviewed article showcases the remarkable clinical results, robust safety profile, and exceptional patient compliance observed during the trials.The study, featured in the European Journal of Internal Medicine, delves into the comprehensive analysis of AD04's liver safety profile compared to a placebo in individuals with AUD and a specific genetic profile. With AUD posing significant health risks and contributing to alcohol-associated liver disease (ALD), the need for effective treatments is paramount.
Remarkably, low-dose AD04 demonstrated minimal impact on liver injury markers, such as ALT, AST, and Serum Bilirubin, compared to placebo. Notably, the treatment did not adversely affect GGT levels, a key indicator of alcohol consumption, further underscoring its safety and tolerability. The study also highlighted AD04's outstanding safety profile, with a low occurrence of adverse events and high medication compliance, a rarity in alcohol treatment literature.
Cary Claiborne, CEO of Adial, hailed the publication as a significant milestone in addressing the critical needs of individuals suffering from AUD and ALD. He emphasized AD04's potential to revolutionize AUD treatment by offering a precision medication tailored to individuals with a specified genetic background.
With AD04 paving the way for precision treatments, tailored interventions for AUD patients could soon become a reality. This groundbreaking advancement not only promises to curb alcohol consumption but also holds the potential to mitigate liver damage in affected populations, offering hope to millions worldwide.
Technical Outlook
Adial Pharmaceuticals, Inc. (
ADIL) stock is trading above the respective Moving Averages (MA) with a Relative Strength Index (RSI) of 65.30 indicating room for continuous growth. 
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.